Elevation Oncology, Inc. (ELEV)
Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations.
We utilize our deep expertise in developing drugs for rare, genomically-defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.
Our lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have recently been identified as oncogenic driver alterations and that we believe have the potential to be therapeutically actionable through targeted HER3 inhibition.
In July 2020, we initiated our Phase 2 CRESTONE trial as the first clinical trial of seribantumab, an anti-HER3 monoclonal antibody, in patients with solid tumors driven by an NRG1 fusion.
We have designed CRESTONE as a tumor-agnostic trial with the potential for registration through an accelerated approval pathway, subject to continued discussions with the FDA.
|IPO Date||Jun 25, 2021|
|CEO||Shawn Leland, Pharm.D., R.Ph.|
888 Seventh Ave., 12th Floor
New York, NY 10106
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Shawn M. Leland Pharm.D., R.Ph.||Founder, President, Chief Executive Officer and Director|
|Joseph J. Ferra Jr.||Chief Financial Officer|
|Tammy Furlong CPA, P.M.P.||Vice President of Finance and Accounting and Secretary|
|Brian Sullivan||Vice President of Corporate Development|